Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6897736 | 0.99 | HSD11B1 (0.42) | HSD11B1HCAR3HCAR2KDM1AKIF11 | |
| SCHEMBL6685193 | 0.82 | HTR2C (0.46) | HSD11B1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6896770 | 0.81 | HTR2C (0.48) | HSD11B1MEN1KMT2A | |
| SCHEMBL6899454 | 0.79 | HSD11B1 (0.39) | HSD11B1HCAR3HCAR2 | |
| SCHEMBL6897711 | 0.77 | HSD11B1 (0.62) | HSD11B1MEN1KMT2A | |
| SCHEMBL25799587 | 0.77 | GRIN1 (0.39) | HSD11B1MEN1KMT2A | |
| SCHEMBL22733040 | 0.77 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL25799597 | 0.76 | GRIN1 (0.46) | HSD11B1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6894594 | 0.76 | HSD11B1 (0.60) | HSD11B1MEN1KMT2A | |
| SCHEMBL6891948 | 0.75 | HSD11B1 (0.42) | HSD11B1HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143964-B1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-03-24 | — | — | EP | claimed |
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | claimed |
| JP-2002535360-A | — | — | 2002-10-22 | — | — | JP | claimed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | claimed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | claimed |
| EP-1143964-B1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-03-24 | — | — | EP | disclosed |
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |